Pfizer Alleges Inconsistencies in Moderna's Statements to FD

In a recent brief to the Patent Trial and Appeal Board, Pfizer told PTAB judges that Moderna’s dismissal of prior art listed in Pfizer’s August 2023 petition for inter partes review of Moderna’s patent on mRNA vaccine technology is inconsistent with its declarations to the FDA.

Related Keywords

United States , Kathi Vidal , Andrew Hirshfeld , Belcher Pharmaceuticals , Trademark Office , International Patent App , Pfizer , Initiative For Medicines , Drug Administration , Patent Trial , Appeal Board , International Patent , United States Patent , Federal Register , Senator Patrick Leahy , Senator Thom Tillis , Cir Sept ,